These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 39023099

  • 1. Early Conversion to Everolimus Within 180 Days of Living Donor Liver Transplantation.
    Rudzik KN, Schonder KS, Humar A, Johnson HJ.
    Clin Transplant; 2024 Jul; 38(7):e15402. PubMed ID: 39023099
    [Abstract] [Full Text] [Related]

  • 2. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
    Lin M, Mittal S, Sahebjam F, Rana A, Sood GK.
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
    [Abstract] [Full Text] [Related]

  • 3. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

  • 4. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
    Sommerer C, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F.
    Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
    [Abstract] [Full Text] [Related]

  • 5. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 6. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
    Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein CG, Nadalin S, Lehner F, Settmacher U, Gotthardt D, Loss M, Ladenburger S, Wimmer P, Dworak M, Schlitt HJ.
    Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
    [Abstract] [Full Text] [Related]

  • 8. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M.
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [Abstract] [Full Text] [Related]

  • 9. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
    Manzia TM, Angelico R, Toti L, Grimaldi C, Sforza D, Vella I, Tariciotti L, Lenci I, Breshanaj G, Baiocchi L, Tisone G.
    Transplant Proc; 2018 Sep; 50(1):175-183. PubMed ID: 29407305
    [Abstract] [Full Text] [Related]

  • 10. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
    Tönshoff B, Ettenger R, Dello Strologo L, Marks SD, Pape L, Tedesco-Silva H, Bjerre A, Christian M, Meier M, Martzloff ED, Rauer B, Ng J, Lopez P.
    Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
    [Abstract] [Full Text] [Related]

  • 11. Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry.
    Saliba F, Dharancy S, Salamé E, Conti F, Eyraud D, Radenne S, Antonini T, Guillaud O, Guguenheim J, Neau-Cransac M, Demartin E, Lasailly G, Duvoux C, Sobesky R, Coilly A, Tresson S, Cailliez V, Boillot O, Pageaux GP, Samuel D, Calmus Y, Dumortier J.
    Liver Transpl; 2020 Nov; 26(11):1465-1476. PubMed ID: 32869469
    [Abstract] [Full Text] [Related]

  • 12. Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.
    Skalioti C, Marinaki S, Darema M, Lionaki S, Antonakopoulos N, Zavos G, Boletis J.
    Transplant Proc; 2015 Nov; 47(6):1705-10. PubMed ID: 26293038
    [Abstract] [Full Text] [Related]

  • 13. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
    De Simone P, Saliba F, Dong G, Escrig C, Fischer L.
    Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
    [Abstract] [Full Text] [Related]

  • 14. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y, Danguilan R, Casasola C, Chang SS, Ruangkanchanasetr P, Kee T, Wong HS, Kenmochi T, Amante AJ, Shu KH, Ingsathit A, Bernhardt P, Hernandez-Gutierrez MP, Han DJ, Kim MS.
    Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
    [Abstract] [Full Text] [Related]

  • 15. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Oct; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.
    Ann Transplant; 2015 Nov 26; 20():707-13. PubMed ID: 26608590
    [Abstract] [Full Text] [Related]

  • 17. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators.
    Am J Transplant; 2016 Apr 26; 16(4):1238-47. PubMed ID: 26820618
    [Abstract] [Full Text] [Related]

  • 18. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.
    Budde K, Sommerer C, Rath T, Reinke P, Haller H, Witzke O, Suwelack B, Baeumer D, Sieder C, Porstner M, Arns W.
    J Nephrol; 2015 Feb 26; 28(1):115-23. PubMed ID: 25192833
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study.
    Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparampil J, Sips C, Kaneko S, Levy G.
    Am J Transplant; 2018 Jun 26; 18(6):1435-1446. PubMed ID: 29237235
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.
    Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, Settmacher U, Heyne N, Clavien PA, Muehlbacher F, Morard I, Wolters H, Vogel W, Becker T, Sterneck M, Lehner F, Klein C, Kazemier G, Pascher A, Schmidt J, Rauchfuss F, Schnitzbauer A, Nadalin S, Hack M, Ladenburger S, Schlitt HJ.
    Am J Transplant; 2012 Jul 26; 12(7):1855-65. PubMed ID: 22494671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.